Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study
09:46am, Thursday, 27'th May 2021
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
Sanofi and GlaxoSmithKline begin Phase 3 study of COVID-19 vaccine candidate
05:59am, Thursday, 27'th May 2021
French pharmaceutical group Sanofi [s:fr: san] and U.K. drug company GlaxoSmithKline said they have begun global Phase 3 efficacy studies of their jointly produced COVID-19 candidate. The randomized,
New Covid-19 Vaccine Will Be Produced This Year As Sanofi, GSK Launch Phase 3 Trial
05:39am, Thursday, 27'th May 2021
One part of the trial will test the vaccine against the South African variant of the virus.
35 Graham Formula Value Dogs Sport 26 Ideal June Dividend Payers
01:33pm, Wednesday, 26'th May 2021
"Benjamin Graham Value Stocks match the criteria. Benjamin Graham followed." -YCharts Value Screener. These 35 Graham Formula Picks were screened by YCharts for revenue, assets, long-term debt, and EP
Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters
08:05am, Tuesday, 25'th May 2021
Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax soon. Mexico's health regulator Cofepris
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings
08:11am, Monday, 24'th May 2021
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY)
3 Dividend Stocks That Should Pay You the Rest of Your Life
06:54am, Sunday, 23'rd May 2021
It's hard to beat dividend-paying stocks -- they offer reliable income as well as stock-price appreciation.
Sanofi: Underestimated Vaccine Potential
03:47pm, Friday, 21'st May 2021
Expected approval of the COVID vaccine at the end of 2021 will allow the company to close the gap in multipliers compared to its closest competitors.
Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients
02:01pm, Thursday, 20'th May 2021
Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Societ
Better Buy for 2021: GlaxoSmithKline or Sanofi?
06:08am, Thursday, 20'th May 2021
These are two cheap stocks in an overvalued market.
Sanofi: Evaluating The Recent Dividend Hike
11:33am, Wednesday, 19'th May 2021
Sanofi has increased its annual payout by 12%+. Compared to historic trends, this increase is way above normal.
Sanofi: Our vaccine could serve as an excellent booster shot
11:16am, Tuesday, 18'th May 2021
Thomas Triomphe, EVP at Sanofi Pasteur, discusses preliminary data from a Phase 2 trial for the drugmaker's Covid-19 vaccine developed in partnership with GlaxoSmithKline.
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
11:16am, Tuesday, 18'th May 2021
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the
Sanofi releases vaccine study results, Dr Gottlieb comments on mask-wearing
02:09pm, Monday, 17'th May 2021
Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to m
Sanofi Executives Say Covid Vaccine Could Be 'Universal Booster'
10:59am, Monday, 17'th May 2021
Yet competition with Pfizer and Moderna could still be stiff.
